Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 32
Filter
Add more filters










Publication year range
1.
Diabetes Obes Metab ; 13(5): 439-45, 2011 May.
Article in English | MEDLINE | ID: mdl-21255215

ABSTRACT

AIM: Endothelial microparticles (EMPs) and endothelial progenitor cells (EPCs) are markers of endothelial injury and repair. We compared the effects of pioglitazone versus metformin on the circulating numbers of EMPs and EPCs in patients with newly diagnosed type 2 diabetes. METHODS: This was a randomized, double-blind, comparator-controlled, 24-week single-centre trial conducted in a Teaching Hospital in Naples, Italy. One hundred and ten people with newly diagnosed type 2 diabetes who were never treated with antihyperglycaemic drugs and had haemoglobin A1c (HbA1c) levels between 7 and 10% were given pioglitazone hydrochloride (15-45 mg/day) (n = 55) or metformin (1000-2000 mg/day) (n = 55) as an active comparator. Absolute change from baseline to final visit in circulating EMPs and EPCs and their ratio were the main outcomes. RESULTS: Baseline characteristics did not differ between the study groups. The decrease in circulating EMPs CD31+ [intergroup difference, -32 counts/µl (95% CI -51 to -9)] and the increase in EPCs CD34+/KDR+ [intergroup difference, 33 cells/10(6) events (95% CI 13 to 55)] were greater with pioglitazone versus metformin. EMPs/EPCs ratio was reduced with pioglitazone and unchanged with metformin [difference, -1.5 (95% CI -2.6 to -0.5), p < 0.001]. Participants assigned to pioglitazone gained more weight and experienced greater improvements in some coronary risk measures [high-density lipoprotein (HDL)-cholesterol, triglycerides, adiponectin and C-reactive protein (CRP)] than did those assigned to metformin. CONCLUSION: Compared with metformin, pioglitazone treatment improved the imbalance between endothelial damage and repair capacity and led to more favourable changes in coronary risk factors in patients with newly diagnosed type 2 diabetes.


Subject(s)
Coronary Artery Disease/prevention & control , Diabetes Mellitus, Type 2/drug therapy , Diabetic Angiopathies/prevention & control , Endothelium, Vascular/drug effects , Hypoglycemic Agents/therapeutic use , Metformin/therapeutic use , Thiazolidinediones/therapeutic use , Adult , Aged , Body Mass Index , Cell Survival/drug effects , Coronary Artery Disease/epidemiology , Diabetes Mellitus, Type 2/epidemiology , Diabetic Angiopathies/epidemiology , Double-Blind Method , Endothelial Cells/drug effects , Female , Humans , Hypoglycemic Agents/adverse effects , Italy/epidemiology , Male , Metformin/adverse effects , Middle Aged , Pioglitazone , Stem Cells/drug effects , Thiazolidinediones/adverse effects
3.
Diabetologia ; 41(10): 1127-32, 1998 Oct.
Article in English | MEDLINE | ID: mdl-9794097

ABSTRACT

Studies have shown that a high plasma non-esterified fatty acid concentration may inhibit glucose induced insulin secretion in vitro and in vivo. The effect of lowering the fatty acid concentration on the acute insulin response was investigated in first degree relatives of people with Type II diabetes in a double-blind, randomised, placebo-controlled trial. Fifty first degree relatives of people with Type II diabetes volunteered for the study. Twenty five were given acipimox (250 mg/day, four times daily) and 25 placebo. The group treated with acipimox had a lower 2-h plasma glucose concentration (6.1 +/- 0.2 vs 7.7 +/- 0.3 vs mmol/l, p < 0.01); better insulin-mediated glucose uptake (35.4 +/- 0.5 vs 28.3 +/- 0.4 mumol/kg fat free mass per min, p < 0.01), acute insulin response (68 +/- 4.4 vs 46 +/- 7.3 mU/l, p < 0.01) and respiratory quotient (0.81 +/- 0.02 vs 0.77 +/- 0.03, p < 0.05); and a rise in the plasma glucagon (164 +/- 63 vs 134 +/- 72 ng/1, p < 0.05), growth hormone (1.31 +/- 0.13 vs 0.97 +/- 0.21 microgram/l, p < 0.03) and cortisol (325 +/- 41 vs 284 +/- 139 nmol/l, p < 0.05) concentrations. The difference in the acute insulin response persisted, even after adjustment for the 2-h plasma glucose concentration, insulin-mediated glucose uptake, the fasting plasma glucagon concentration and the growth hormone concentration (p < 0.05). In a subgroup of eight patients acipimox was compared with acipimox plus intralipid. The acute insulin response (44 +/- 5.1 vs 71 +/- 5.3 mU/l, p < 0.01) and the insulin-mediated glucose uptake (27.4 +/- 0.4 vs 36.7 +/- 0.5 mumol/kg fat free mass per min, p < 0.003) were lower with acipimox plus intralipid treatment than with acipimox alone. It is concluded that long term acipimox treatment lowers the plasma fasting free fatty acid concentration and improves the acute insulin response and the insulin mediated glucose uptake.


Subject(s)
Diabetes Mellitus, Type 2/genetics , Diabetes Mellitus, Type 2/physiopathology , Fatty Acids, Nonesterified/blood , Hypolipidemic Agents , Insulin/metabolism , Pyrazines , Adult , Blood Glucose/metabolism , Body Composition , Double-Blind Method , Fasting , Female , Glucagon/blood , Human Growth Hormone/blood , Humans , Hydrocortisone/blood , Insulin/blood , Insulin Secretion , Male , Middle Aged , Oxygen Consumption , Placebos , Pyrazines/administration & dosage
4.
Aesthetic Plast Surg ; 22(3): 222-4, 1998.
Article in English | MEDLINE | ID: mdl-9618189

ABSTRACT

A case is reported of late infection in a breast implant, in a 35-year-old female who underwent breast augmentation with a double-lumen silicone prosthesis combined with abdominoplasty. After 8 uneventful postoperative months, untoward and poorly defined symptoms occurred and further exploratory surgery became necessary. Due to a subacute inflammatory process in the entire pocket of the left breast, the implants were removed. Culture demonstrated Klebsiella pneumoniae. After complete healing, a pair of texturized moderate profile implants was placed above the muscle through an areolar access. The clinical history and management of this unusual case are described.


Subject(s)
Breast Implantation , Breast Implants/adverse effects , Klebsiella Infections , Klebsiella pneumoniae , Prosthesis-Related Infections/microbiology , Adult , Female , Humans
5.
Aesthetic Plast Surg ; 21(5): 342-5, 1997.
Article in English | MEDLINE | ID: mdl-9299002

ABSTRACT

Expanded polytetrafluoroethylene (ePTFE) was used in conjunction with autologous fat and silicone prosthesis to reshape the facial contour in a patient with mild Parry-Romberg syndrome (PRS). Patches of ePTFE were implanted in the temporo-malar and parotidean areas, fat was injected into the genian area and lower lip, and a middle-density solid silicone device was implanted in the chin. No complications were observed. The correction remained stable at follow-up 24 months post-op, permitting facial movements without alterations in contour. As far as we know, there has been no previous experience of ePTFE use in the treatment of PRS reported.


Subject(s)
Facial Hemiatrophy/surgery , Polytetrafluoroethylene , Adult , Humans , Male , Prostheses and Implants , Temporal Muscle/surgery
6.
J Clin Endocrinol Metab ; 81(12): 4244-8, 1996 Dec.
Article in English | MEDLINE | ID: mdl-8954022

ABSTRACT

In vitro studies have demonstrated that free fatty acids (FFA) may enhance oxidative stress. In contrast, no in vivo studies have addressed such a relationship. This four-part study aims at investigating the association between FFA and oxidative stress in healthy volunteers. The following experimental procedures were carried out: 1) determination and simple correlations among fasting plasma FFA, glucose, insulin, plasma thiobarbituric acid-reactive substance (TBARS), the ratio of reduced glutathione (GSH) to oxidized GSH, and lipid hydroperoxide (n = 30); 2) time-dependent effect of FFA on plasma TBARS concentrations and GSH/oxidized GSH ratio (n = 10); 3) dose-dependent effect of FFA on plasma TBARS concentrations (n = 9); and 4) relationship among plasma FFA concentrations, plasma TBARS concentrations, and insulin action (n = 11). The results demonstrate that fasting plasma FFA concentrations correlated with fasting plasma TBARS concentrations (r = 0.65; P < 0.001) and lipid hydroperoxide (r = 0.79; P < 0.001). The correlation between plasma FFA and TBARS remained significant even after adjustment for age, sex, body mass index, and fasting and 2-h plasma glucose concentrations (r = 0.43; P < 0.01). In the time-dependent study, plasma TBARS concentrations increased with the rise in plasma FFA concentrations. In the dose-response study, a progressive increase in fasting plasma FFA concentrations was achieved by varying the Intralipid infusion rate, which also caused plasma TBARS concentrations to increase progressively until they reached a plateau between the last two infusion rates (0.3 and 0.4 mL/min). A euglycemic hyperinsulinemic glucose clamp (insulin infusion rate, 10.2 pmol/kg min for 360 min) was also performed. Simultaneous 10% Intralipid (0.4 mL/min) infusion significantly enhanced plasma TBARS concentrations and inhibited insulin-stimulated whole body glucose disposal (WBGD). GSH infusion (15 mg/min for 360 min) had opposite effects on plasma TBARS concentrations and WBGD. A combined infusion of 10% Intralipid and GSH was associated with a stimulation of WBGD with a magnitude midway between that of 10% Intralipid and GSH infused separately. In conclusion, fasting plasma FFA seems to enhances oxidative stress, which might contribute to the disruptive effects of plasma FFA on insulin-mediated glucose uptake.


Subject(s)
Fatty Acids, Nonesterified/blood , Insulin/pharmacology , Oxidative Stress , Adult , Blood Glucose/analysis , Calcium/metabolism , Female , Glutathione/metabolism , Humans , Insulin/blood , Male
7.
Aesthetic Plast Surg ; 20(6): 503-11, 1996.
Article in English | MEDLINE | ID: mdl-8929327

ABSTRACT

The author describes a personal technique for moderate-to-large breast hypertrophy, regardless of the degree of ptosis, based upon a personal experience of more than 200 breast reductions. It is a superior monopedicle nipple-areola flap procedure, which leaves an inverted-T scar. It was used in 35 cases over the last 3 years involving tissue reductions ranging from 500 to 1950 g per gland. All patients underwent follow-up evaluations 1, 3, 6, and 12 months after surgery. No complications were observed, and areolar sensation was preserved in all cases. Apart from its effectiveness in cases of massive hypertrophy and the absence of difficulties related to elevation of the nipple-areola complex, the equatorial technique offers the significant advantages of a simple preoperative marking phase and well-defined, reproducible parameters for reduction and reshaping. These characteristics reduce the need for subjective judgment and, therefore, the risk of error. The results obtained are highly satisfactory in terms of volume reduction, form, and symmetry.


Subject(s)
Breast/abnormalities , Mammaplasty , Adolescent , Adult , Female , Humans , Lipectomy
8.
J Am Coll Nutr ; 14(4): 387-92, 1995 Aug.
Article in English | MEDLINE | ID: mdl-8568117

ABSTRACT

OBJECTIVE: Our study investigated the metabolic benefits deriving from chronic pharmacological vitamin C administration in aged non-insulin dependent (Type II) diabetic patients. METHODS: Forty type II diabetic patients (age: 72 +/- 0.5 years) underwent placebo and vitamin C (0.5 g twice daily) administration in double-blind, randomized, cross-over fashion. All patients were treated by oral hypoglycaemic agents which continued throughout the study. After baseline observations, treatment periods lasted 4 months and were separated by a 30-day wash-out period. RESULTS: Patients' antropometric data were unchanged throughout the study. Chronic vitamin C administration vs placebo was associated with a significant decline in fasting plasma free radicals (0.26 +/- 0.06 vs 0.49 +/- 0.07 p < 0.03) and insulin (90 +/- 4 vs 73 +/- 6 pmol/L p < 0.04), total- (7.3 +/- 0.5 vs 5.8 +/- 0.4 mmol/L p < 0.03), LDL-cholesterol (5.6 +/- 0.6 vs 4.1 +/- 0.3 mmol/L p < 0.05) and triglycerides (2.58 +/- 0.07 vs 2.08 +/- 0.04 mmol/L p < 0.04) levels. In 20 patients, chronic vitamin C administration improved whole body glucose disposal and nonoxidative glucose metabolism. Percent increase in plasma vitamin C levels correlated with the percent decline in plasma LDL-cholesterol (r = 0.44; p < 0.007) and insulin levels (r = 0.42; p < 0.006). Finally percent increase in plasma vitamin C levels was correlated with the percent decline in plasma free radicals and increase in GSH levels. CONCLUSIONS: Chronic vitamin C administration has beneficial effects upon glucose and lipid metabolism in aged non-insulin dependent (type II) diabetic patients.


Subject(s)
Ascorbic Acid/therapeutic use , Diabetes Mellitus, Type 2/diet therapy , Diabetes Mellitus, Type 2/metabolism , Glucose/metabolism , Lipids/blood , Aged , Ascorbic Acid/pharmacology , Cross-Over Studies , Dose-Response Relationship, Drug , Double-Blind Method , Female , Food, Fortified , Glucose Clamp Technique , Glycated Hemoglobin/analysis , Humans , Insulin/blood , Male
9.
Eur J Clin Invest ; 25(7): 529-33, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7556372

ABSTRACT

Hypertensive patients with left ventricular hypertrophy (LVH) have a higher degree of hyperinsulinaemia than hypertensive patients without LVH. Obese patients with LVH have also been demonstrated to have a very low glucose disappearance rate after an intravenous glucose bolus. No studies have investigated the difference in insulin action and substrate oxidation in hypertensive patients with and without LVH. For this reason 36 subjects were enrolled for our study: (1) healthy control subjects (n = 10); (2) hypertensive patients without LVH (n = 12); and (3) hypertensive patients with LVH (n = 14). All subjects underwent an oral glucose tolerance test (OGTT, 75 g of glucose) and a euglycaemic hyperinsulinaemic glucose clamp (insulin infusion rate, 7.1 pmol (kg min)-1 for 120 min). In this latter test indirect calorimetry allowed substrate oxidation determination. Echocardiographic methods allowed LVH assessment. Hypertensive patients with LVH had the lowest insulin-mediated nonoxidative glucose metabolism compared to hypertensive patients without LVH (P < 0.01) and to healthy subjects (P < 0.001). In the whole group of hypertensive patients (n = 26), partial correlations showed left ventricular mass index (LVMI) associated with fasting plasma insulin levels (r = 0.44 P < 0.005), insulin-mediated whole body glucose disposal (r = -0.41 P < 0.01) and nonoxidative glucose metabolism (r = -0.33 P < 0.04) independently of age, body weight, systolic blood pressure and plasma catecholamines levels. In conclusion, our data provide evidence that LVH in hypertensive patients is associated with a worsening in nonoxidative glucose metabolism.


Subject(s)
Blood Glucose/metabolism , Glucose/metabolism , Hypertension/metabolism , Hypertrophy, Left Ventricular/metabolism , Insulin/pharmacology , Blood Glucose/drug effects , Case-Control Studies , Female , Glucose Clamp Technique , Glucose Tolerance Test , Humans , Hypertension/blood , Hypertension/complications , Hypertrophy, Left Ventricular/blood , Hypertrophy, Left Ventricular/complications , Infusions, Intravenous , Insulin/administration & dosage , Male , Middle Aged , Oxidation-Reduction , Reference Values
10.
J Hum Hypertens ; 9(7): 541-6, 1995 Jul.
Article in English | MEDLINE | ID: mdl-7562882

ABSTRACT

Thirty elderly, mildly hypertensive patients were enrolled for a single-blind, randomised cross-over placebo controlled trial in which placebo and lisinopril (20 mg/day before breakfast) were given for 4 and 8 weeks, respectively. A wash-out period of 3 weeks between placebo and lisinopril was observed. In each patient a euglycaemic glucose clamp with simultaneous indirect calorimetry allowed us to determine whole body glucose disposal and substrate oxidation. Changes in morning SBP and DBP were also determined. Lisinopril vs. placebo significantly improved whole body glucose disposal (40.4 +/- 0.4 vs. 30.3 +/- 0.4 mumol/kg LBM x min; P < 0.01), non-oxidative glucose metabolism (18.1 +/- 0.7 vs. 10.9 +/- 0.6 mumol/kg LBM x min; P < 0.01) and fasting plasma potassium levels (4.8 +/- 3 vs. 4.4 +/- 0.4 mmol/l; P < 0.05). SBP (175 +/- 3.3 vs. 160 +/- 3.0 mm Hg; P < 0.001) and DBP (106 +/- 2.3 vs. 95 +/- 2.0 mm Hg; P < 0.001) were significantly reduced by lisinopril administration. After ACE inhibition, fasting plasma potassium levels correlated with the decline in mean arterial BP (r = -0.71; P < 0.006). In conclusion, lisinopril administration reduces arterial BP and improves insulin sensitivity in elderly hypertensive patients.


Subject(s)
Aging/physiology , Hypertension/drug therapy , Hypertension/physiopathology , Insulin/pharmacology , Lisinopril/therapeutic use , Aged , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Blood Glucose/metabolism , Cross-Over Studies , Electrolytes/blood , Female , Humans , Insulin/blood , Lisinopril/adverse effects , Male , Single-Blind Method
11.
Eur J Clin Pharmacol ; 48(5): 333-8, 1995.
Article in English | MEDLINE | ID: mdl-8641319

ABSTRACT

Fourteen hypertensive (174.3/98.3 mmHg) non-diabetic patients were given a euglyceamic glucose clamp along with infusion of 0.9% NaCl and the prostacyclin (PGI2) analogue Iloprost (0.7 ng x kg x min(-1)). Substrate oxidation was also determined by indirect calorimetry. Over the last 60 min of the clamp, Iloprost vs saline improved whole body glucose disposal (WBGD) (35 vs 28.3 micromol x kg(-1) LBM) and non-oxidative glucose metabolism (24.7 vs 18.1 micromol x kg(-1) LBM x min(-1). Iloprost delivery was associated with a significant decrease in membrane microviscosity (0.253 vs 0.205), but did not affect arterial blood pressure and heart rate. In nine patients, skeletal muscle blood flow (SMBF) and insulin-stimulated glucose uptake (GU) were also studied. At the end of the study, despite a similar SMBF (37 vs 38 ml x min(-1) x kg(-1)), GU (0.55 vs 0.46 mmol x l(-1)) was significantly increased by Iloprost infusion. Percentage decrease in membrane microviscosity was correlated with percentage increase in WBGD (r = 0.65) and non-oxidative glucose metabolism (r = 0.68). In conclusion, low-dose Iloprost infusion improves insulin action and non-oxidative glucose metabolism in hypertensive patients.


Subject(s)
Blood Glucose/drug effects , Blood Glucose/metabolism , Hypertension/blood , Hypertension/drug therapy , Iloprost/therapeutic use , Insulin/therapeutic use , Vasodilator Agents/therapeutic use , Blood Pressure/drug effects , Cell Membrane/drug effects , Dose-Response Relationship, Drug , Drug Synergism , Epoprostenol/biosynthesis , Epoprostenol/blood , Female , Glucose/pharmacokinetics , Heart Rate/drug effects , Humans , Hypertension/physiopathology , Iloprost/adverse effects , Infusions, Intravenous , Insulin Resistance , Male , Middle Aged , Muscle, Skeletal/blood supply , Oxidation-Reduction , Vasodilator Agents/adverse effects , Viscosity
12.
Metabolism ; 43(11): 1426-9, 1994 Nov.
Article in English | MEDLINE | ID: mdl-7968598

ABSTRACT

Ten healthy subjects and 30 non-insulin-dependent (type II) diabetic patients matched for age, gender ratio, body mass index, lean body mass (LBM), waist to hip ratio, and arterial blood pressure volunteered for the study. In all subjects, fasting plasma free radical (O2-) levels and basal membrane lipid fluidity (MLF) and protein mobility (MPM) were determined. The whole group of subjects underwent a euglycemic hyperinsulinemic glucose clamp with simultaneous indirect calorimetry for substrate oxidation determination. Diabetic patients versus controls displayed higher fasting plasma glucose (8.3 +/- 0.4 v 5.1 +/- 0.4 mmol/L, P +/- .001), O2- (0.48 +/- 0.02 v 0.16 +/- 0.02 mumol/L x min), and hemoglobin A1c ([HbA1C] 7.9% +/- 0.4% v 5.7% +/- 0.3%, P < .03) levels and a stronger reduction in basal MLF (0.243 +/- 0.006 v 0.318 +/- 0.009, P < .003) and basal MPM (0.348 +/- 0.003 v 0.518 +/- 0.010, P < .002). Whole-body glucose disposal (WBGD) and oxidative and nonoxidative glucose metabolism were also significantly lower in diabetics than in controls. In diabetic patients (n = 30), plasma O2- levels correlated with basal MLF (r = -.59, P < .005), basal MPM (r = -.84, P < .001), fasting plasma insulin level (r = .51, P < .004), WBGD (r = -.53, P < .002), and nonoxidative (r = -.45, P < .01) glucose metabolism. In conclusion, our results demonstrate that a relationship between plasma O2- levels and insulin action occurs in non-insulin-dependent diabetics.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/metabolism , Insulin/blood , Oxidative Stress , Reactive Oxygen Species/metabolism , Aged , Diabetes Mellitus, Type 2/physiopathology , Female , Glucose Clamp Technique , Humans , Male
13.
Diabete Metab ; 19(2): 230-8, 1993.
Article in English | MEDLINE | ID: mdl-8339854

ABSTRACT

In order to evaluate whether the presence of a positive family history of diabetes (PFH) may have a negative impact on both glucose metabolism and cardiovascular risk factors, we studied parameters of carbohydrate metabolism (fasting and 2h-plasma glucose, HbA1c) and beta-cell function (fasting insulin and C-peptide), as well as the levels of some established cardiovascular risk factors (total cholesterol and triglycerides, HDL-cholesterol, blood pressure) in 729 subjects who were seen within the frame of a Regional Health Program in Taranto, South Italy. According to the NDDG criteria, 147 men and 235 women had normal glucose tolerance, 54 men and 66 women non-diagnostic OGTT, 65 men and 79 women impaired glucose tolerance, and 45 men and 58 women newly-diagnosed Type 2 diabetes. There was a continuous increase of PFH across the categories of glucose intolerance (p < 0.001). Subjects with PFH were younger (4 years on the average) than subjects without PFH. After adjustment for age, there was no difference in the clinical and metabolic parameters considered across the categories of glucose tolerance between subjects with or without PFH. Only in OGTT-diagnosed diabetics, was the presence of PFH associated with significantly greater levels of total cholesterol and 2h-plasma glucose, as well as a trend for triglycerides and HbA1c to be higher. There was a continuous increase in fasting glucose, HbA1c, insulin and C-peptide across the categories; however, the C-peptide/insulin molar ratio was lowest in OGTT-diagnosed diabetics. There was a graded and significant increase in the levels of cardiovascular risk factors across the categories.(ABSTRACT TRUNCATED AT 250 WORDS)


Subject(s)
Blood Glucose/metabolism , Cardiovascular Diseases/genetics , Diabetes Mellitus, Type 1/genetics , Adult , Aged , Female , Glucose Tolerance Test , Humans , Male , Middle Aged , Reference Values , Retrospective Studies , Risk Factors
14.
In. Canada. Major Industrial Accidents Council of Canada (MIACC); Canada. Air and Waste Management Association. Conference proceedings : The practical approach to hazardous substances accidents. Saint John, New Brunswick, Canada. Major Industrial Accidents Council of Canada;Canada. Environment Canada;Canada. Air and Waste Management Association, 1993. p.1-13, ilus.
Monography in En | Desastres -Disasters- | ID: des-7969

ABSTRACT

The HSE makes routine use of its computerised quantified Risk assessment tool (RISKAT) in order to assess the risks from mayor industrial hazards. In recent years attention has been directed towards the transport of danguerous substances and consequently the HSE has developed a transportation version of RISKAT. This paper describes the application of Transport RISKAT to a case study in which the overall risks from a major industrial facility handling chlorine have been assessed. A novel feature of this study is the inclusion of the delivery system into the assessment, and the comparison of two transport modes - road and rail. The proposed switch from rail to road transport significantly reduces the risks from site operations. The study therefore addresses two questions : has any transfer of risks onto the transport system taken place, and if so, are the overall risks reduced as a result of the switch in mode?. The report includes that although litte evidence for a transfer for risks associated with the site to risks associated with the transport system was found, there was a considerable degree of incertainty in the final risk estimates. Therefore, further investigation into the relative probability of road and rail tanker breaches is recommended in order to enable definitive conclusions to be drawn (AU)


Subject(s)
Chlorine , Pollutants Transport , Risk Assessment , Industrial Safety , United Kingdom , Disaster Planning , Disaster Planning
15.
Eur J Clin Pharmacol ; 43(1): 39-45, 1992.
Article in English | MEDLINE | ID: mdl-1505607

ABSTRACT

The effect of the calcium antagonist nicardipine on insulin secretion and glucose homoeostasis was investigated in elderly hypertensives with and without diabetes mellitus; 15 patients with essential hypertension for at least 10 years and normal glucose tolerance according to standard criteria (Group I) and 15 elderly hypertensive patients affected by Type 2 diabetes mellitus and on treatment with diet or oral drugs (Group 2). In the basal state, all patients were submitted to an oral glucose tolerance test (OGTT, 75 g) and an iv arginine test (30 g), on two different days and in random order. The same tests were repeated after one month of treatment with nicardipine 60 mg/day, in three spaced doses, the last being given 1 h before the post-treatment test. Nicardipine did not change overall glucose homoestasis, as assessed by haemoglobin Alc and fructosamine, nor did it significantly affect the plasma insulin response either to glucose or arginine in Groups 1 and 2. Only the glucagon response to arginine was significantly reduced in diabetic hypertensives. Small, non-significant variations in the metabolic and hormonal parameters were seen in additional two groups of patients (Groups 3 and 4), matched with Groups 1 and 2 for age, sex and diseases, who took capsules containing placebo. Thus, nicardipine did not produce any significant overall alteration in glucose homoestasis when given to elderly diabetic or nondiabetic hypertensive subjects.


Subject(s)
Blood Glucose/metabolism , Diabetes Mellitus, Type 2/metabolism , Homeostasis/drug effects , Hypertension/metabolism , Nicardipine/pharmacology , Aged , Arginine/pharmacology , C-Peptide/blood , Diabetes Mellitus, Type 2/complications , Female , Glucagon/blood , Glucagon/metabolism , Glucose Tolerance Test , Humans , Hypertension/complications , Insulin/blood , Male , Reproducibility of Results
17.
Minerva Chir ; 45(23-24): 1469-75, 1990 Dec.
Article in Italian | MEDLINE | ID: mdl-2087280

ABSTRACT

In a double blind, controlled clinical study, 40 patients, 20 of whom were subjected to mastectomy or quadrantectomy and 20 to inguinal hernioplasty, were randomly assigned to two treatment groups of 20 subjects each, balanced by type of operation. Treatment lasted 3 days and involved the administration of 3 suppositories per day of nimesulide or diclofenac sodium. Independently of the type of operation, a significant reduction in pain symptomatology (spontaneous pain, pain on active and passive movements) and in inflammatory symptomatology (hyperaemia and tumefaction) and a good control of body temperature was observed for both treatment groups. No changes in arterial pressure or laboratory examinations were observed in either group, nor there were any noteworthy adverse reactions.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Diclofenac/therapeutic use , Inflammation/prevention & control , Pain, Postoperative/prevention & control , Postoperative Complications/prevention & control , Sulfonamides/therapeutic use , Adult , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Diclofenac/administration & dosage , Double-Blind Method , Female , Humans , Inflammation/drug therapy , Male , Middle Aged , Pain, Postoperative/drug therapy , Postoperative Complications/drug therapy , Sulfonamides/administration & dosage , Suppositories
18.
Minerva Endocrinol ; 15(2): 149-51, 1990.
Article in Italian | MEDLINE | ID: mdl-2098658

ABSTRACT

Several experimental data have documented the ability of both opiates and opioid peptides to stimulate food intake. On the other hand, the plasma beta-endorphin levels found in obese patients are higher than those observed in normal-weight controls, which may have pathogenetic implications. We have investigated the responses of plasma glucose, insulin, C-peptide and glucagon to an infusion of human beta-endorphin in formerly obese subjects who had obtained by dieting the normalization of body weight and in lean controls. The data show that: a) the increased plasma beta-endorphin concentrations found in human obesity are not corrected by normalization of body weight; b) formerly obese subjects behave as obese subjects in their metabolic and hormonal responses to beta-endorphin.


Subject(s)
Obesity/blood , beta-Endorphin/blood , Adult , Female , Humans , Male
19.
Waterloo; Canada. Institute for Risk Research; Jul. 1989. 144 p. tab.
Monography in En | Desastres -Disasters- | ID: des-9874
20.
Waterloo; Canada. University of Waterloo; Sep. 1988. 149 p. ilus, tab.
Monography in En | Desastres -Disasters- | ID: des-9878
SELECTION OF CITATIONS
SEARCH DETAIL
...